ASND
Ascendis Pharma A/S
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Ascendis Pharma A/S
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Annual filing, covered
20-F parsed · Feb 11 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Feb 11 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Expected move
No implied move.
—
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Ascendis Pharma A/S.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Ascendis Pharma A/S.
Ascendis Pharma A/S
256.35
−1.58 · −0.61%
—
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $2.7B | 15.20% | 0.00% |
| T. Rowe Price | $1.8B | 9.98% | +9.62% |
| venBio Select Advisor | $1.4B | 7.55% | +0.96% |
| Westfield | $1.3B | 7.09% | −0.32% |
| Jupiter Topco | $973.4M | 5.39% | — |
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $2.7B | 15.20% | 0.00% |
| T. Rowe Price | $1.8B | 9.98% | +9.62% |
| venBio Select Advisor | $1.4B | 7.55% | +0.96% |
| Westfield | $1.3B | 7.09% | −0.32% |
| Jupiter Topco | $973.4M | 5.39% | — |
Linked news
News
Tall tick = annual report · Source: EDGAR